Syntis

Today, we shared that the first participant has been dosed in the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101 for #obesity, as well as key new additions to our executive team. Read more here: businesswire.com/news/home/2026…

Today we announce a $38 million financing, including a $33M Series A led by Cerberus Ventures. This is an exciting moment for Syntis, accelerating our vision to revolutionize both chronic and #raredisease treatment through safe, effective oral therapies. businesswire.com/news/home/2025…

A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an alternative to surgeries and GLP-1 drugs. wired.com/story/syntis-b…

A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an alternative to surgeries and GLP-1 drugs. wired.com/story/syntis-b…

Today we announced positive preclinical and first-in-human data for our lead candidate, SYNT-101, an investigational once-daily oral treatment for #obesity at the European Congress on Obesity and Weight Management. Read more: businesswire.com/news/home/2025…

Seeking to carve out its own niche in the obesity space, @SyntisBio launched on Tuesday to develop an oral weight-loss treatment that mimics the effects of gastric bypass surgery. #pharma #biospace hubs.li/Q02BlGqC0

.@SyntisBio launches for oral obesity, rare disease drugs bioworld.com/articles/709451 #biotech #pharma

Today, we launch to revolutionize oral therapy for obesity, diabetes and rare diseases by unlocking the full therapeutic potential of the small intestine! Read more below: syntis.bio/syntis-bio-lau…